Independent and not affiliated with the FDA, MHRA, ISPE, PDA, or any agency. Get the appgoutham@madhadi.com
madhadi.comData Integrity & GxP Quality
Browse all topics → Articles Templates & Procedures Learning paths GlossaryScenariosToolsRegulatory ReferencesLearning PathsTopics About Start here
Plan Plug-and-play starting point Data Integrity

Plan: Data Integrity Remediation Program Plan

A plug-and-play program plan for a data integrity remediation after a warning letter or non-compliance finding: workstreams, governance and cadence, the retrospective review, commitment management, third-party verification, milestones, and the transition to sustainable compliance, with a worked specimen.

Document type: Plan

Read and copy the template below into your own quality system. It is a generic starting point for your own internal use, provided as is, with no warranty; see the Terms and License. Adopting it does not by itself create compliance.

This is a ready-to-use program plan for a data integrity (DI) remediation. It is the governing document above the individual CAPAs and protocols: it sets the workstreams, the governance cadence, the retrospective review, commitment tracking, and the path to sustainable compliance. Replace every <<FILL: ...>> placeholder with your own specifics and route it through your program governance. A worked filled specimen follows. Verify each cited regulation against the current source before you rely on it.

Document control header

FieldEntry
Document titleData Integrity Remediation Program Plan, <<FILL: SITE>>
Document number<<FILL: PLAN-ID, e.g. REM-PLAN-001>>
Version<<FILL: version>>
Effective date<<FILL: date>>
Executive sponsor<<FILL: name, role>>
Program manager<<FILL: name, role>>
Regulatory trigger<<FILL: warning letter / 483 / non-compliance statement, date and reference>>

1. Scope and objective

Remediate the DI findings in <<FILL: reference>> and the systemic failures that allowed them, at <<FILL: SITE>>, to a state the agency will judge adequate at a follow-up inspection, and then embed the preventive controls into the routine quality system so the failures cannot return. Scope covers the observed findings and the systems, procedures, training, culture, and data implicated by them, not only the specific items named.

2. Approach and risk basis

The program addresses each observation as a symptom of a system. Every observation maps to its cited regulation and the systems it touches (see the Day 1 triage worksheet), and remediation is sequenced so the systems tied to released product are fixed first. The retrospective review determines the true scope; new findings loop back into containment and CAPA and are disclosed in writing. Timelines are set honestly; the program is planned to run <<FILL: e.g. 18-36>> months and to be non-linear.

3. Workstreams

#WorkstreamFocusTypical durationPrimary owner
1Immediate containmentStop active risk; manual compensating controls0-2 monthsQA + operations
2Technical remediationAudit trails, access, backup, time sync, validation6-24 monthsIT / CSV / engineering
3Procedural remediationDI policy and supporting SOPs, not generic2-9 monthsQuality systems
4TrainingRole-based DI training with effectiveness checks2-12 months, then ongoingTraining + QA
5Culture and leadershipThe conditions that allowed the failuresContinuousSite leadership
6Retrospective data reviewDetermine true scope and product impact3-18 monthsQC + QA + forensics

Compensating controls in workstream 1 are explicitly temporary; the plan states when each is replaced by a validated control, and they are not lifted early.

4. Governance and cadence

BodyFrequencyChairPurpose
Workstream lead meetingWeeklyProgram managerStatus, blockers, new findings
Steering committeeMonthlyExecutive sponsorDecisions, resources, agency posture
New-findings reviewStanding agenda itemQAAssess, disclose, route to CAPA

Every workstream reports in the same format: percent complete, milestones met versus planned, open risks, and any new findings.

5. Commitment and disclosure management

  • Maintain a single commitment register listing every promise made in every response, its due date, owner, and status; review it at every steering committee.
  • Any finding discovered during the retrospective review is disclosed to the agency in writing. Withholding a finding is treated as a breach of the response commitment.
  • If a committed date cannot be met, communicate in advance with the reason and a revised date.

6. Retrospective data review

The review scope, boundary rationale, systems, reconciliation methodology, classification of findings, product impact, and disclosure are defined in the retrospective review protocol. The program plan requires that the review boundary be risk-justified and documented, and that an independent reviewer confirm the methodology.

7. Third-party verification

For a significant remediation, an independent third party reviews the program and attests to its completeness and durability. The plan defines the third party’s scope in writing, gives it real access, and lets it report without editing. Its independence is stated in the engagement letter.

8. Deliverables

DeliverableReferenceOwner
Day 1 observation triage worksheet<<FILL>>Program manager
Integrated project plan<<FILL>>Program manager
Initial and detailed responses<<FILL>>Regulatory affairs
DI policy and supporting SOPs<<FILL>>Quality systems
System remediation and revalidation records<<FILL>>IT / CSV
Retrospective review protocol and report<<FILL>>QC + QA
Commitment register<<FILL>>Program manager
Third-party verification report<<FILL>>Executive sponsor
Sustainability handoff to the routine QMS<<FILL>>Head of Quality

9. Schedule and milestones

MilestoneTarget dateDependency
Executive sponsor and PMO named<<FILL>>-
Written response submitted<<FILL: within 15 business days>>Containment underway
Retrospective review scope approved<<FILL>>Triage complete
Technical remediation of release-critical systems<<FILL>>-
Retrospective review complete and disclosed<<FILL>>-
Follow-up inspection readiness<<FILL>>All workstreams
Sustainability handoff<<FILL>>Closeout

10. Acceptance criteria for the program

  • Every observation is mapped to its regulation and system and addressed at correction, corrective, and preventive levels.
  • The retrospective review is complete, its boundary risk-justified, and all findings disclosed.
  • Systems are remediated and revalidated, procedures are specific to the real gaps, and training has effectiveness evidence.
  • All commitments in every response were met on their dates, or renegotiated in advance.
  • The preventive controls are embedded in the routine quality system with named owners.

11. References

FDA, Data Integrity and Compliance With Drug CGMP: Questions and Answers (2018). MHRA, GXP Data Integrity Guidance and Definitions (2018). WHO Guideline on Data Integrity (Technical Report Series, 2021) (reference by title; describe, do not paste). PIC/S PI 041, Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (2021) (reference by title; describe, do not paste). ICH Q10, Pharmaceutical Quality System, for management review and the sustainable state. 21 CFR Part 211 and 21 CFR Part 11 for the underlying US requirements.

Confirm the current version and clause numbers of each reference before issue.

12. Revision history

VersionDateAuthorSummary of change
<<FILL: 1.0>><<FILL: date>><<FILL>>Initial program plan.

13. Approvals

RoleNameSignatureDate
Executive sponsor<<FILL>>
Program manager<<FILL>>
Head of Quality<<FILL>>

Filled specimen

The following shows the plan header and governance completed for an illustrative site. Details are illustrative.

  • Trigger: Warning Letter WL-000-2026 citing disabled CDS audit trails, shared LIMS logins, and unexplained “trial” injections.
  • Executive sponsor: VP Site Quality; program manager: full-time, supported by a two-person PMO.
  • Planned duration: 24 months, non-linear, with the retrospective review expected to surface additional findings.
  • Cadence: weekly workstream leads, monthly steering committee chaired by the sponsor, new findings a standing agenda item.
  • First milestones: written response at day 14; retrospective scope approved at week 6; release-critical CDS remediated by month 6.

This plan reads as a program under control: a senior sponsor who can release resources, a full-time PMO, a realistic non-linear timeline, and a governance structure that expects and discloses new findings rather than hiding them.

Common inspection findings this plan prevents

  • Remediation run as a single CAPA with no program structure, so scope and ownership blur.
  • An executive sponsor too junior to release budget, so the program stalls.
  • A retrospective review left to whoever has spare time, so the true scope is never determined.
  • Compensating controls lifted before the validated control is in place.
  • The program disbanding with no handoff, so controls quietly drift once the team disperses.

How to adapt this plan

  1. Name a senior executive sponsor and a full-time program manager before anything else.
  2. Map the workstreams to your actual findings and sequence release-critical systems first.
  3. Set an honest, non-linear timeline and a governance cadence that surfaces new findings.
  4. Stand up the commitment register and the disclosure discipline from day one.
  5. Define the sustainability handoff so the preventive controls live in the routine QMS after closeout.
Use madhadi.com as an app Full screen, works offline, one tap from your home screen.